Kaposi's sarcoma medical therapy

Jump to navigation Jump to search

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Kaposi's sarcoma Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Kaposi's sarcoma from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Study of Choice

Staging

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

Chest X Ray

Echocardiograph and Ultrasound

CT

MRI

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Kaposi's sarcoma medical therapy On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Kaposi's sarcoma medical therapy

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Kaposi's sarcoma medical therapy

CDC on Kaposi's sarcoma medical therapy

Kaposi's sarcoma medical therapy in the news

Blogs on Kaposi's sarcoma medical therapy

Directions to Hospitals Treating Kaposi's sarcoma

Risk calculators and risk factors for Kaposi's sarcoma medical therapy

Please help WikiDoc by adding more content here. It's easy! Click here to learn about editing.

Overview

Patients with Kaposi's sarcoma have many treatment options. The selection depends on the stage of the tumor. The options are local therapy, radiation therapy, chemotherapy, biologic drugs treatment, or a combination of these methods. Before treatment starts, ask your health care team about possible side effects and how treatment may change your normal activities. Because cancer treatments often damage healthy cells and tissues, side effects are common. Side effect may not be the same for each person, and they may change from one treatment session to the next.

Medical Therapy

Kaposi's sarcoma is not curable, in the usual sense of the word, but it can often be effectively palliated for many years and this is the aim of treatment. In KS associated with immunodeficiency or immunosuppression, treating the cause of the immune system dysfunction can slow or stop the progression of KS. In 40% or more of patients with AIDS-associated Kaposi's sarcoma, the Kaposi lesions will shrink upon first starting highly active antiretroviral therapy (HAART). However, in a certain percentage of such patients, Kaposi's sarcoma may again grow after a number of years on HAART, especially if HIV is not completely suppressed. Patients with a few local lesions can often be treated with local measures such as radiation therapy or cryotherapy. Surgery is generally not recommended as Kaposi's sarcoma can appear in wound edges.

Therapies

  • Local therapy:
    • Topical treatment: This is the treatment to put medicine directly on the lesions.
    • Cryosurgery: During this procedure, the doctor use a probe cooled with liquid nitrogen to freeze the lesions.
    • Intralesional chemotherapy: In this procedure, the chemotherapy drug is injected directly into the Kaposi's sarcoma lesions.
  • Radiation therapy: This is a cancer treatment to kill cancer cells or keep them from growing by using high-energy x-rays or other types of radiation.
  • Biologic therapy: This treatment uses chemicals such as interferon alpha to help the immune system attack cancer cells.

Antimicrobial Regimen

  • Human herpesvirus 8 (KSHV)
  • 1. Mild to moderate Kaposi sarcoma[1]
  • Preferred regimen: initiate or optimize ART
  • 2. Advanced Kaposi sarcoma (ACTG Stage T1, including disseminated cutaneous or visceral Kaposi sarcoma)
  • Preferred regimen: chemotherapy (per oncology consult) AND ART
  • 3. Primary effusion lymphoma
  • Preferred regimen: chemotherapy (per oncology consult) AND ART
  • Note: Valganciclovir PO or Ganciclovir IV can be used as adjunctive therapy.
  • 4. Multicentric Castleman's disease
  • Preferred regimen (1): Valganciclovir 900 mg PO bid for 3 weeks
  • Preferred regimen (2): Ganciclovir 5 mg/kg IV q12h for 3 weeks
  • Preferred regimen (3): Valganciclovir 900 mg PO BID AND Zidovudine 600 mg PO q6h for 7–21 days
  • Alternative regimen: Rituximab 375 mg/m2 given weekly for 4–8 weeks (may be an alternative to or used adjunctively with antiviral therapy)

References

  1. "Guidelines for Prevention and Treatment of Opportunistic Infections in HIV-Infected Adults and Adolescents" (PDF).

Template:WH Template:WS